Cargando…

Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial

INTRODUCTION: Magnetic resonance imaging (MRI) is increasingly used in patients with rheumatoid arthritis (RA) to determine residual inflammation after treatment and as a predictor of structural damage progression. Establishing an optimal threshold of inflammatory activity that predicts lower risk o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmad, Harris A., Baker, Joshua F., Østergaard, Mikkel, Ye, June, Emery, Paul, Conaghan, Philip G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822846/ https://www.ncbi.nlm.nih.gov/pubmed/31278695 http://dx.doi.org/10.1007/s12325-019-01020-6

Ejemplares similares

Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis
por: Ahmad, Harris A., et al.
Publicado: (2020)

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial
por: Conaghan, Philip G, et al.
Publicado: (2011)

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
por: Ahmad, Harris A., et al.
Publicado: (2022)

Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2011)

Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis
por: Conaghan, Philip G., et al.
Publicado: (2019)

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study
por: Peterfy, Charles, et al.
Publicado: (2016)

Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) patients (PREDICTRA)
por: Emery, Paul, et al.
Publicado: (2018)

Rheumatoid Arthritis Relapse and Remission – Advancing Our Predictive Capability Using Modern Imaging
por: Terslev, Lene, et al.
Publicado: (2021)

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
por: Peterfy, Charles, et al.
Publicado: (2016)

Modulation of peripheral T-cell function by interleukin-7 in rheumatoid arthritis
por: Churchman, Sarah M, et al.
Publicado: (2014)

Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission
por: Terslev, Lene, et al.
Publicado: (2021)

Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D Scales
por: Covic, Tanya, et al.
Publicado: (2009)

Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis
por: Østergaard, Mikkel, et al.
Publicado: (2022)

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis
por: Rakieh, Chadi, et al.
Publicado: (2014)

Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis
por: Mortimer, Isabel, et al.
Publicado: (2019)

A multi-modal MRI study of the central response to inflammation in rheumatoid arthritis
por: Schrepf, Andrew, et al.
Publicado: (2018)

Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis
por: McQueen, Fiona M., et al.
Publicado: (2017)

Polyphenols Targeting MAPK Mediated Oxidative Stress and Inflammation in Rheumatoid Arthritis
por: Behl, Tapan, et al.
Publicado: (2021)

Conventional radiography requires a MRI-estimated bone volume loss of 20% to 30% to allow certain detection of bone erosions in rheumatoid arthritis metacarpophalangeal joints
por: Ejbjerg, Bo Jannik, et al.
Publicado: (2006)

Targeting Probiotics in Rheumatoid Arthritis
por: Bungau, Simona Gabriela, et al.
Publicado: (2021)

The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy
por: Conaghan, Philip G, et al.
Publicado: (2014)

Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques
por: Conaghan, Philip G, et al.
Publicado: (2016)

Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis
por: Bywall, Karin Schölin, et al.
Publicado: (2021)

Whole-Body Magnetic Resonance Imaging Assessment of Joint Inflammation in Rheumatoid Arthritis—Agreement With Ultrasonography and Clinical Evaluation
por: Ng, Sin Ngai, et al.
Publicado: (2020)

Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
por: Emery, Paul, et al.
Publicado: (2020)

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2016)

Future therapeutic targets in rheumatoid arthritis?
por: Cheung, Tommy Tsang, et al.
Publicado: (2017)

Metabolites as drivers and targets in rheumatoid arthritis
por: Hanlon, Megan M, et al.
Publicado: (2021)

Ferroptosis as an emerging target in rheumatoid arthritis
por: Zhao, Hui, et al.
Publicado: (2023)

Androgens in rheumatoid arthritis: when are they effectors?
por: Cutolo, Maurizio
Publicado: (2009)

Placebo-Related Adverse Events in Rheumatoid Arthritis
por: Sharma, Ratna Shree, et al.
Publicado: (2022)

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
por: Nagy, György, et al.
Publicado: (2022)

Viewpoint: Glucocorticoids in the treatment of rheumatoid arthritis: points to (re)consider
por: Boers, Maarten
Publicado: (2023)

NK4 therapy: a new approach to target angiogenesis and inflammation in rheumatoid arthritis
por: Rabquer, Bradley J, et al.
Publicado: (2013)

The application value of MRI in the diagnosis of subclinical inflammation in patients with rheumatoid arthritis in remission
por: Zhang, Huimei, et al.
Publicado: (2018)

Treating rheumatoid arthritis to target: recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2010)

Changes in the pharmacological management of rheumatoid arthritis over two decades
por: Crossfield, Samantha S R, et al.
Publicado: (2021)

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
por: van Vollenhoven, Ronald F, et al.
Publicado: (2016)

Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies
por: Ikeda, Keigo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cvrcu7bk107cg2kvt7fepfrm8h